Check-Cap (NASDAQ:CHEK) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report sent to investors on Wednesday morning. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Stock Down 13.5 %

Shares of CHEK opened at $0.67 on Wednesday. The business has a fifty day moving average of $0.85 and a 200 day moving average of $1.06. The company has a market cap of $3.92 million, a PE ratio of -0.22 and a beta of 0.19. Check-Cap has a 52-week low of $0.56 and a 52-week high of $3.04.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.